HER2-Positive Solid Tumors Clinical Trial
Official title:
An Open-Label, Dose Escalation Phase I Clinical Trial on Safety, Tolerability and Pharmacokinetics of BAT8001 for Injection in Patients With HER2-Positive Solid Tumors
An Open-Label, Dose Escalation Phase I Clinical Trial on Safety, Tolerability and Pharmacokinetics of BAT8001 for Injection in Patients with HER2-Positive Solid Tumors (breast cancer or gastric cancer)。
This is an open-label, dose escalation Phase I clinical study in two stages. Stage 1 consists of the first four cycles where the tolerability, safety, pharmacokinetics and immunogenicity of BAT8001 for injections will be studied and preliminary efficacy will be evaluated. Efficacy and safety assessments continue from the fifth cycle until disease progression or intolerable toxicities. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04280341 -
JS001 in Combination With RC48-ADC in Treatment of HER2-Positive Advanced Malignant Solid Tumors
|
Phase 1 | |
Active, not recruiting |
NCT04278144 -
A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04660929 -
CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors
|
Phase 1 | |
Completed |
NCT04521179 -
Study of KN026 Combined With KN046 in Patients With Locally Advanced HER2-positive Solid Tumors
|
Phase 2 | |
Not yet recruiting |
NCT04501770 -
A Study of M802 (HER2 and CD3) in HER2-Positive Advanced Solid Tumors
|
Phase 1 |